Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. Wedzicha (London, United Kingdom). Optimising bronchodilator therapy in COPD: Who, why and when?. International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care

Member's Comments

No comment yet.

Related content which might interest you: Improving symptomology in COPD: which therapy would you choose, a brochodilator or pulmonary rehabilitation? Source: International Congress 2019 – Hot topics in pulmonary rehabilitation Year: 2019 Long-acting bronchodilators in COPD: where are we now and where are we going? Source: Breathe 2014; 10:110-120 Year: 2014 Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: Lung function and safety Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Inhaled therapies: can they breathe new life into asthma? Source: International Congress 2019 – The journey towards personalized medicine in asthma: where are we now? Year: 2019 Inhaled treatment of COPD: A delphi consensus statement Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 What to use INSTEAD of inhaled corticosteroids in COPD? Source: Eur Respir J 2014; 44: 1391-1393 Year: 2014 Do obese asthmatics have a worse bronchodilator response? Source: International Congress 2015 – Monitoring airway diseases with lung function tests Year: 2015 Are bronchodilator drugs really useful in COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 94s Year: 2001 Inhaled corticosteroids in treatment of patients with intermittent bronchial asthma: yes or no? Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005 Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 In whom should regular asthma controller therapy be initiated? Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Optimising COPD prevention: what do the doctors need? Source: Annual Congress 2007 - Smoking and the lung Year: 2007 How to treat asthma in 2021? Goodbye SABA, hello MART and welcome triple therapy Source: Virtual Congress 2021 – Airway diseases Year: 2021 The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014 Inhaled medication: which device for which patient? Source: Eur Respir Monogr 2015; 69: 213-223 Year: 2015 Is therapy adherence to inhaled corticosteroids related to hospitalization, pneumonia or mortality in COPD? Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014